Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Current Colorectal Cancer Reports
Published in: Current Colorectal Cancer Reports 3/2013

01-09-2013 | Adjuvant Therapy for Colon Cancers (AB Benson III and A de Gramont, Section Editors)

Functions and Clinical Implications of Autocrine VEGF Signaling in Colorectal Cancer

Authors: Annette K. Larsen, Aimery de Gramont, Virginie Poindessous, Anaïs Bouygues, Mériam Ayadi, Paul Mésange

Published in: Current Colorectal Cancer Reports | Issue 3/2013

Login to get access

Abstract

Vascular endothelial growth factor (VEGF) signaling is linked to invasiveness and aggressive disease in colorectal cancer (CRC), and two VEGF-directed agents, bevacizumab and aflibercept, are currently approved for treatment of metastatic disease. CRC cells are a major source of VEGF that is secreted into the tumor environment where it can associate with VEGF receptors on neighboring endothelial cells thereby promoting tumor angiogenesis. In addition, the CRC cells express functional VEGF receptors giving rise to autocrine VEGF signaling. So far, the biological and clinical implications of autocrine VEGF signaling have attracted less attention than the classical paracrine VEGF signaling pathways. In this review we focus on the effect of autocrine VEGF signaling on the survival, invasion, and drug-resistance of CRC cells and on the prognostic value of expression of VEGF ligands and receptors in CRC patients. We then discuss the different factors associated with a therapeutic response to VEGF blockage and summarize future challenges.
Literature
1.
Chung AS, Lee J, Ferrara N. Targeting the tumour vasculature: insights from physiological angiogenesis. Nat Rev Cancer. 2010;10:505–14.PubMedCrossRef
2.
• Vlajnic T, Andreozzi MC, Schneider S, et al. VEGFA gene locus (6p12) amplification identifies a small but highly aggressive subgroup of colorectal cancer [corrected] patients. Mod Pathol. 2011;24:1404–12. The authors show that VEGF amplification in patients with colorectal cancer is associated with a remarkably aggressive disease characterized by a high incidence of vascular invasion.PubMedCrossRef
3.
Papadopoulos N, Martin J, Ruan Q, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis. 2012;15:171–85.PubMedCrossRef
4.
5.
Cross MJ, Dixelius J, Matsumoto T, et al. VEGF-receptor signal transduction. Trends Biochem Sci. 2003;28:488–94.PubMedCrossRef
6.
Alitalo K, Carmeliet P. Molecular mechanisms of lymphangiogenesis in health and disease. Cancer Cell. 2002;1:219–27.PubMedCrossRef
7.
•• Bates RC, Goldsmith JD, Bachelder RE, et al. Flt-1-dependent survival characterizes the epithelial-mesenchymal transition of colonic organoids. Curr Biol. 2003;13:1721–7. This article identifies VEGFR1 as a survival factor for invasive CRC cells and demonstrates its expression in tumor cells from patients with colorectal cancer.PubMedCrossRef
8.
Fan F, Wey JS, McCarty MF, et al. Expression and function of vascular endothelial growth factor receptor-1 on human colorectal cancer cells. Oncogene. 2005;24:2647–53.PubMedCrossRef
9.
Giatromanolaki A, Koukourakis MI, Sivridis E, et al. Activated VEGFR2/KDR pathway in tumour cells and tumour associated vessels of colorectal cancer. Eur J Clin Invest. 2007;37:878–86.PubMedCrossRef
10.
Calvani M, Trisciuoglio D, Bergamaschi C, et al. Differential involvement of vascular endothelial growth factor in the survival of hypoxic colon cancer cells. Cancer Res. 2008;68:285–91.PubMedCrossRef
11.
Morelli MP, Brown AM, Pitts TM, et al. Targeting vascular endothelial growth factor receptor-1 and -3 with cediranib (AZD2171): effects on migration and invasion of gastrointestinal cancer cell lines. Mol Cancer Ther. 2009;8:2546–58.PubMedCrossRef
12.
• Poindessous V, Ouaret D, El Ouadrani K, et al. EGFR- and VEGF(R)-targeted small molecules show synergistic activity in colorectal cancer models refractory to combinations of monoclonal antibodies. Clin Cancer Res. 2011;17:6522–30. This work shows that joint targeting of VEGF(R) and EGFR by two small molecules inhibits intracrine signaling and is more effective than combinations of two monoclonal antibodies targeting the same pathways.PubMedCrossRef
13.
André T, Kotelevets L, Vaillant JC, et al. Vegf, Vegf-B, Vegf-C and their receptors KDR, FLT-1 and FLT-4 during the neoplastic progression of human colonic mucosa. Int J Cancer. 2000;86:174–81.PubMedCrossRef
14.
Yin Y, Cao LY, Wu WQ, et al. Blocking effects of siRNA on VEGF expression in human colorectal cancer cells. World J Gastroenterol. 2010;16:1086–92.PubMedCrossRef
15.
Eppenberger M, Zlobec I, Baumhoer D, et al. Role of the VEGF ligand to receptor ratio in the progression of mismatch repair-proficient colorectal cancer. BMC Cancer. 2010;10:93.PubMedCrossRef
16.
Okita NT, Yamada Y, Takahari D, et al. Vascular endothelial growth factor receptor expression as a prognostic marker for survival in colorectal cancer. Jpn J Clin Oncol. 2009;39:595–600.PubMedCrossRef
17.
Xu L, Jain RK. Down-regulation of placenta growth factor by promoter hypermethylation in human lung and colon carcinoma. Mol Cancer Res. 2007;5:873–80.PubMedCrossRef
18.
Escudero-Esparza A, Martin TA, Davies ML, et al. PGF isoforms, PLGF-1 and PGF-2, in colorectal cancer and the prognostic significance. Cancer Genomics Proteomics. 2009;6:239–46.PubMed
19.
Sung CY, Son MW, Ahn TS, et al. Expression of placenta growth factor in colorectal carcinomas. J Korean Soc Coloproctol. 2012;28:315–20.PubMedCrossRef
20.
Willett CG, Duda DG, di Tomaso E, et al. Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. J Clin Oncol. 2009;27:3020–6.PubMedCrossRef
21.
Bagley RG, Ren Y, Weber W, et al. Placental growth factor upregulation is a host response to antiangiogenic therapy. Clin Cancer Res. 2011;17:976–88.PubMedCrossRef
22.
Munaut C, Lorquet S, Pequeux C, et al. Hypoxia is responsible for soluble vascular endothelial growth factor receptor-1 (VEGFR-1) but not for soluble endoglin induction in villous trophoblast. Hum Reprod. 2008;23:1407–15.PubMedCrossRef
23.
Bais C, Wu X, Yao J, et al. PlGF blockade does not inhibit angiogenesis during primary tumor growth. Cell. 2010;141:166–77.PubMedCrossRef
24.
Van de Veire S, Stalmans I, Heindryckx F, et al. Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease. Cell. 2010;141:178–90.PubMedCrossRef
25.
• Yao J, Wu X, Zhuang G, et al. Expression of a functional VEGFR-1 in tumor cells is a major determinant of anti-PlGF antibodies efficacy. Proc Natl Acad Sci USA. 2011;108:11590–5. This study indicates that effective PlGF-directed therapy is linked to inhibition of VEGFR1 signaling in the tumor cells rather than to inhibition of tumor angiogenesis.PubMedCrossRef
26.
•• Masuda K, Teshima-Kondo S, Mukaijo M, et al. A novel tumor-promoting function residing in the 5′ non-coding region of vascular endothelial growth factor mRNA. PLoS Med. 2008;5:e94. This pivotal study revealed an important effect of VEGF on tumor cell survival mediated by both VEGF mRNA and VEGF protein.PubMedCrossRef
27.
Samuel S, Fan F, Dang LH, et al. Intracrine vascular endothelial growth factor signaling in survival and chemoresistance of human colorectal cancer cells. Oncogene. 2011;30:1205–12.PubMedCrossRef
28.
Lesslie DP, Summy JM, Parikh NU, et al. Vascular endothelial growth factor receptor-1 mediates migration of human colorectal carcinoma cells by activation of Src family kinases. Br J Cancer. 2006;94:1710–7.PubMed
29.
Larsen AK, Ouaret D, El Ouadrani K, et al. Targeting EGFR and VEGF(R)pathway cross-talk in tumor survival and angiogenesis. Pharmacol Ther. 2011;131:80–90.PubMedCrossRef
30.
Shweiki D, Neeman M, Itin A, et al. Induction of vascular endothelial growth factor expression by hypoxia and by glucose deficiency in multicellspheroids: implications for tumor angiogenesis. Proc Natl Acad Sci USA. 1995;92:768–72.PubMedCrossRef
31.
Maxwell PH, Dachs GU, Gleadle JM, et al. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci USA. 1997;94:8104–9.PubMedCrossRef
32.
Carmeliet P, Dor Y, Herbert JM, et al. Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature. 1998;394:485–90.PubMedCrossRef
33.
Hu CJ, Sataur A, Wang L, et al. The N-terminal transactivation domain confers target gene specificity of hypoxia-inducible factors HIF-1alpha and HIF-2alpha. Mol Biol Cell. 2007;18:4528–42.PubMedCrossRef
34.
35.
Stein I, Neeman M, Shweiki D, et al. Stabilization of vascular endothelial growth factor mRNA by hypoxia and hypoglycemia and coregulation with other ischemia-induced genes. Mol Cell Biol. 1995;15:5363–8.PubMed
36.
Gerber HP, Condorelli F, Park J, et al. Differential transcriptional regulation of the two vascular endothelial growth factor receptor genes. Flt-1, but not Flk-1/KDR, is up-regulated by hypoxia. J Biol Chem. 1997;272:23659–67.PubMedCrossRef
37.
Han Y, Kuang SZ, Gomer A, et al. Hypoxia influences the vascular expansion and differentiation of embryonic stem cell cultures through the temporal expression of vascular endothelial growth factor receptors in an ARNT-dependent manner. Stem Cells. 2010;28:799–809.PubMedCrossRef
38.
Suzuma K, Takagi H, Otani A, et al. KDR/Flk-1 (VEGFR-2) in murine model of ischemia-induced retinal neovascularization. Microvasc Res. 1998;56:183–91.PubMedCrossRef
39.
Kanellis J, Paizis K, Cox AJ, et al. Renal ischemia-reperfusion increases endothelial VEGFR-2 without increasing VEGF or VEGFR-1 expression. Kidney Int. 2002;61:1696–706.PubMedCrossRef
40.
Graeber TG, Peterson JF, Tsai M, et al. Hypoxia induces accumulation of p53 protein, but activation of a G1-phase checkpoint by low-oxygen conditions is independent of p53 status. Mol Cell Biol. 1994;14:6264–77.PubMedCrossRef
41.
Menendez D, Krysiak O, Inga A, et al. A SNP in the flt-1 promoter integrates the VEGF system into the p53 transcriptional network. Proc Natl Acad Sci USA. 2006;103:1406–11.PubMedCrossRef
42.
• Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012;487:330–7. This multi-center study provided novel insight into genetic alterations associated with colorectal cancer.CrossRef
43.
Hwang I, Kim J, Jeong S. β-Catenin and peroxisome proliferator-activated receptor-δ coordinate dynamic chromatin loops for the transcription of vascular endothelial growth factor A gene in colon cancer cells. J Biol Chem. 2012;287:41364–73.PubMedCrossRef
44.
• Naik S, Dothager RS, Marasa J, et al. Vascular endothelial growth factor receptor-1 is synthetic lethal to aberrant {beta}-catenin activation in colon cancer. Clin Cancer Res. 2009;15:7529–37. This study revealed that functional VEGFR1 is a positive mediator of the wnt/beta-catenin pathway in colorectal cancer cells.PubMedCrossRef
45.
Goldman CK, Kim J, Wong WL, et al. Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology. Mol Biol Cell. 1993;4:121–33.PubMedCrossRef
46.
Detmar M, Brown LF, Claffey KP, et al. Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis. J Exp Med. 1994;180:1141–6.PubMedCrossRef
47.
Petit AM, Rak J, Hung MC, et al. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol. 1997;151:1523–30.PubMed
48.
Ciardiello F, Bianco R, Damiano V, et al. Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. Clin Cancer Res. 2000;6:3739–47.PubMed
49.
Pore N, Jiang Z, Gupta A, et al. EGFR tyrosine kinase inhibitors decrease VEGF expression by both hypoxia-inducible factor (HIF)-1-independent and HIF-1-dependent mechanisms. Cancer Res. 2006;66:3197–204.PubMedCrossRef
50.
Li X, Lu Y, Liang K, et al. Requirement of hypoxia-inducible factor-1alpha down-regulation in mediating the antitumor activity of the anti-epidermal growth factor receptor monoclonal antibody cetuximab. Mol Cancer Ther. 2008;7:1207–17.PubMedCrossRef
51.
•• Viloria-Petit A, Crombet T, Jothy S, et al. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer Res. 2001;61:5090–101. This study provides evidence of a close link between EGFR signaling and VEGF secretion which has important therapeutic implications.PubMed
52.
Shaheen RM, Ahmad SA, Liu W, et al. Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors. Br J Cancer. 2001;85:584–9.PubMedCrossRef
53.
Sini P, Wyder L, Schnell C, et al. The antitumor and antiangiogenic activity of vascular endothelial growth factor receptor inhibition is potentiated by ErbB1 blockade. Clin Cancer Res. 2005;11:4521–32.PubMedCrossRef
54.
Yokoi K, Thaker PH, Yazici S, et al. Dual inhibition of epidermal growth factor receptor and vascular endothelial growth factor receptor phosphorylation by AEE788 reduces growth and metastasis of human colon carcinoma in an orthotopic nude mouse model. Cancer Res. 2005;65:3716–25.PubMedCrossRef
55.
Tonra JR, Deevi DS, Corcoran E, et al. Synergistic antitumor effects of combined epidermal growth factor receptor and vascular endothelial growth factor receptor-2 targeted therapy. Clin Cancer Res. 2006;12:2197–207.PubMedCrossRef
56.
Naumov GN, Nilsson MB, Cascone T, et al. Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance. Clin Cancer Res. 2009;15:3484–94.PubMedCrossRef
57.
Punt CJ, Tol J. More is less—combining targeted therapies in metastatic colorectal cancer. Nat Rev Clin Oncol. 2009;6:731–3.PubMedCrossRef
58.
Saltz LB, Lenz HJ, Kindler HL, et al. Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. J Clin Oncol. 2007;25:4557–61.PubMedCrossRef
59.
Tol J, Koopman M, Cats A, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med. 2009;360:563–72.PubMedCrossRef
60.
Hecht JR, Mitchell E, Chidiac T, et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol. 2009;27:672–80.PubMedCrossRef
61.
Selvakumaran M, Yao KS, Feldman MD, et al. Antitumor effect of the angiogenesis inhibitor bevacizumab is dependent on susceptibility of tumors to hypoxia-induced apoptosis. Biochem Pharmacol. 2008;75:627–38.PubMedCrossRef
62.
Barr MP, Bouchier-Hayes DJ, Harmey JJ. Vascular endothelial growth factor is an autocrine survival factor for breast tumour cells under hypoxia. Int J Oncol. 2008;32:41–8.PubMed
63.
McIntyre A, Patiar S, Wigfield S, et al. Carbonic anhydrase IX promotes tumor growth and necrosis in vivo and inhibition enhances anti-VEGF therapy. Clin Cancer Res. 2012;18:3100–11.PubMedCrossRef
64.
•• Nardo G, Favaro E, Curtarello M, et al. Glycolytic phenotype and AMP kinase modify the pathologic response of tumor xenografts to VEGF neutralization. Cancer Res. 2011;71:4214–25. The investigators combined imaging and immunohistochemistry to demonstrate that the antitumor effects of angiogenesis inhibition depend, in part, on the metabolic phenotype of the cancer cells.PubMedCrossRef
Metadata
Title
Functions and Clinical Implications of Autocrine VEGF Signaling in Colorectal Cancer
Authors
Annette K. Larsen
Aimery de Gramont
Virginie Poindessous
Anaïs Bouygues
Mériam Ayadi
Paul Mésange
Publication date
01-09-2013
Publisher
Springer US
Published in
Current Colorectal Cancer Reports / Issue 3/2013
Print ISSN: 1556-3790
Electronic ISSN: 1556-3804
DOI
https://doi.org/10.1007/s11888-013-0177-2

Other articles of this Issue 3/2013

Current Colorectal Cancer Reports 3/2013 Go to the issue

Therapeutic Approaches to Metastatic Colorectal Cancers (E Díaz-Rubio, Section Editor)

The Continuum of Care in Chemotherapy Approach to Metastatic Colorectal Cancer

Therapeutic Approaches to Metastatic Colorectal Cancers (E Díaz-Rubio, Section Editor)

Role of Chemotherapy in Peritoneal Carcinomatosis in Metastatic Colorectal Cancer

Adjuvant Therapy for Colon Cancers (AB Benson III and A de Gramont, Section Editors)

The Role of Adjuvant Therapy in the Elderly

Adjuvant Therapy for Colon Cancers (AB Benson III and A de Gramont, Section Editors)

The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6 months) Regimen for Patients with Stage III Colon Cancer: Trial Design and Current Status

Adjuvant Therapy for Colon Cancers (AB Benson III and A de Gramont, Section Editors)

Animal Models to Test Adjuvant Treatment: An Experimental Model of Colon Cancer

Therapeutic Approaches to Metastatic Colorectal Cancer (E Díaz-Rubio, Section Editor)

Management of Toxicity Induced by Anti-EGFR Therapy in Metastatic Colorectal Cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits